{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 63c39167-d664-48d4-87c4-14dbeab1916c --><h2>Changes</h2><!-- end field 63c39167-d664-48d4-87c4-14dbeab1916c -->","summary":null,"htmlStringContent":"<!-- begin item ac48b9b8-ec61-4c65-b735-462cb6016e93 --><!-- begin field 1f02a484-ef24-4d57-b276-8a238a04d64d --><p><strong>June 2019</strong> — minor update. The recommended dose of ceftriaxone has been increased to 1 g [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2019</a>].</p><p><strong>March 2019 </strong>— minor update. Prescribing information for quinolones updated in line with MHRA, 2019, <em>Fluoroquinolone antibiotics: new restrictions and precautions for use due to very rare reports of disabling and potentially long-lasting or irreversible side effects </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">MHRA, 2019</a>].</p><p><strong>January 2019</strong> — minor update. Bullets amended.</p><p><strong>October 2018 </strong>— minor update. Adverse effects updated within prescribing information - metronidazole. </p><p><strong>August 2018</strong> — reviewed. A literature search was conducted in August 2018 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The following changes have been made: </p><ul><li>The role of <em>Mycoplasma genitalium</em> as an important cause of pelvic inflammatory disease (PID) has become clearer, and testing is recommended for women presenting with possible PID and the male partners of women with confirmed <em>M. genitalium</em> infection.</li><li>Moxifloxacin is now recommended as a first-line treatment, especially in women with <em>M. genitalium </em>PID.</li><li>Doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolides, which have been associated with increased resistance in <em>M. genitalium</em>.</li><li>The topic has been restructured.</li></ul><!-- end field 1f02a484-ef24-4d57-b276-8a238a04d64d --><!-- end item ac48b9b8-ec61-4c65-b735-462cb6016e93 -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"ce73b766-9dd9-5e33-8bcf-9ea92aab3ce2","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field c95d20d5-1c7d-475d-97a0-230b024e59b5 --><h3>Previous changes</h3><!-- end field c95d20d5-1c7d-475d-97a0-230b024e59b5 -->","summary":null,"htmlStringContent":"<!-- begin item 6fb3cf26-5b3c-437d-9143-87f7ee260535 --><!-- begin field ca69855e-e850-475e-8a05-a8fbfeeb8a57 --><p><strong>April 2015</strong> — minor update. Link inserted to the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</p><p><strong>March 2013</strong> — reviewed. A literature search was conducted in March 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made.</p><p><strong>February 2013</strong> — minor update. The 2013 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic.</p><p><strong>October 2011</strong> — minor update. The dose of intramuscular ceftriaxone has been increased from 250 mg to 500 mg to reflect the reduced sensitivity of <em>Neisseria gonorrhoeae </em>to cephalosporins and the current UK treatment guidelines for uncomplicated gonorrhoea from the British Association for Sexual Health and HIV. Issued in November 2011.</p><p><strong>May 2011</strong> — minor update. Expanded on the <em>advice </em>and <em>management of sexual partner </em>nodes to include new recommendations from the British Association for Sexual Health and HIV. Also included two new RCTs which suggest that moxifloxacin monotherapy is therapeutically equivalent to other regimens in the treatment of uncomplicated pelvic inflammatory disease (PID) (Heystock and Ross, 2009; Judin et al, 2010). The 2010/2011 QIPP options for local implementation have been added to this topic. Issued in June 2011.</p><p><strong>February 2011</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has advised that moxifloxacin should be restricted to second-line use for the management of PID because of the increased risk of liver reactions and QT prolongation. Issued in February 2011.</p><p><strong>August 2010 </strong>— updated to include oral cefixime 400 mg as a single dose as an alternative to the intramuscular ceftriaxone component of the recommended antibiotic regimens. The lower age limit for quinolone prescriptions has also been raised from 16 to 18 years. Issued in September 2010.</p><p><strong>March to August 2009</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>September 2008</strong> — minor correction to the <em>Changes </em>section. Issued September 2008.</p><p><strong>January to March 2006</strong> — reviewed. Validated in June 2006 and issued in July 2006.</p><p><strong>October 2005</strong> — minor technical update. Issued in November 2005.</p><p><strong>December 2002</strong> — reviewed. Validated in March 2003 and issued in April 2003.</p><p><strong>December 1999</strong> — written. Validated in March 2000 and issued in May 2000.</p><!-- end field ca69855e-e850-475e-8a05-a8fbfeeb8a57 --><!-- end item 6fb3cf26-5b3c-437d-9143-87f7ee260535 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}